Boehringer Ingelheim has over 90 years of heritage in respiratory disease. Since 1921 we have emerged as a leader in this disease area, having launched several treatments in a range of respiratory conditions including asthma, chronic obstructive pulmonary disease (COPD), idiopathic pulmonary fibrosis (IPF) and lung cancer. Our focus is on improving the quality of life of patients suffering from debilitating respiratory diseases and enabling them to maintain a more independent life.
Systemic sclerosis (SSc) is a disfiguring, disabling and potentially fatal rare disease that causes scarring of the skin (scleroderma), lungs (SSc-ILD) and other organs. Worldwide it is estimated that over two million people have systemic sclerosis and it affects mostly women in the prime of their lives, between 25 and 55 years of age. Systemic sclerosis is a complex rare disease with a variable course. It presents with a range of symptoms involving several different organs; this means it is difficult to recognize and this can delay early and accurate diagnosis.
At Boehringer Ingelheim we're proud to partner with Fesca - Federation of European Scleroderma Associations and the great work they do to improve awareness of systemic sclerosis, also referred to as scleroderma. That’s why we're standing "Hand in Hand for
You may have seen that in April we announced our Memorandum of Understanding with the Federation of European Scleroderma Associations (FESCA) and the Scleroderma Society of Canada (SSC). But what does this actually mean?
The memornadum covers the SENSCIS™ Trial (http://bit.ly/1On7Fzl), its extension trial and other areas of collaboration including disease awareness.
Our illustrated factsheet all about systemic sclerosis is our first step to creating greater awareness - find it by clicking here http://bit.ly/1rka5da
You may have seen that in April we announced our Memorandum of Understanding with the Federation...